Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

134.36
+3.862.96%
Post-market: 134.360.00000.00%19:59 EDT
Volume:5.97M
Turnover:798.93M
Market Cap:166.70B
PE:18.27
High:134.52
Open:131.57
Low:131.12
Close:130.50
52wk High:157.29
52wk Low:104.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.09
T/O Rate:0.48%
Dividend:3.19
Dividend Rate:2.37%
EPS(TTM):7.35
EPS(LYR):6.78
ROE:43.36%
ROA:13.29%
PB:7.09
PE(LYR):19.82

Loading ...

SM, Casey’s, Gilead, Dominion, Insulet Trending With Analysts

TIPRANKS
·
Yesterday

Experimental treatments could help US Ebola patient

Reuters
·
Yesterday

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

Movement Alert|Gilead Sciences Rises 3.04% in Regular Trading, Core Drug Trodelvy Receives Positive CHMP Opinion from EMA

Market Focus
·
Yesterday

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (Bulevirtide-Gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (Hdv)

THOMSON REUTERS
·
Yesterday

US FDA approves Gilead's drug for deadly liver infection

Reuters
·
Yesterday

FDA: Approved Hepcludex Injection to Treat Chronic Hepatitis Delta Virus Infection in Adults Without Cirrhosis or With Compensated Cirrhosis

THOMSON REUTERS
·
Yesterday

FACTBOX-Bundibugyo Ebola vaccines and treatments in development

Reuters
·
Yesterday

China's commerce ministry holds meeting with foreign pharmaceutical firms

Reuters
·
May 22

WHO raises risk of Ebola outbreak in Congo to 'very high' at national level

Reuters
·
May 22

BRIEF-Gilead Receives CHMP Positive Opinion For Trodelvy® In First-Line Metastatic Triple-Negative Breast Cancer

Reuters
·
May 22

Gilead receives positive CHMP opinion for Trodelvy in TNBC

TIPRANKS
·
May 22

Gilead Gets Positive Opinion From European Regulators on Breast-Cancer Treatment

Dow Jones
·
May 22

Gilead Trodelvy wins CHMP backing for first-line metastatic triple-negative breast cancer use

Reuters
·
May 22

Gilead Receives Chmp Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for Pd-(L)1 Inhibitors

THOMSON REUTERS
·
May 22

Kite presents updated Phase 1 data for KITE-753 CAR-T in relapsed B-cell lymphoma

Reuters
·
May 22

New Asco and Eha 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

THOMSON REUTERS
·
May 22

Gilead Sciences Closes Tubulis Acquisition

MT Newswires Live
·
May 21

Gilead completes acquisition of Tubulis for $3.15 billion upfront

Reuters
·
May 21

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

THOMSON REUTERS
·
May 21